{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.2","value":"1.1"},{"groupId":"OG001","spread":"0.6","value":"1.5"},{"groupId":"OG002","spread":"0.4","value":"1.7"},{"comment":"Due to insufficient number of participants in this age group (only 1 participant), standard deviation could not be calculated.","groupId":"OG003","spread":"NA","value":"3.8"}]}],"title":"Children (age>=2 & <12 y; n=3, n=9, n=3, n=1)"},{"categories":[{"measurements":[{"comment":"Due to insufficient number of participants in this age group (only 1 participant), standard deviation could not be calculated.","groupId":"OG000","spread":"NA","value":"1.1"},{"comment":"Due to insufficient number of participants in this age group (only 1 participant), standard deviation could not be calculated.","groupId":"OG001","spread":"NA","value":"1.0"},{"groupId":"OG002","spread":"0.6","value":"2.6"},{"comment":"No participants in this age group.","groupId":"OG003","spread":"NA","value":"NA"}]}],"title":"Adolescents (age>=12 & <18 y; n=1; n=1; n=3; n=0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.1","value":"1.1"},{"groupId":"OG001","spread":"0.6","value":"1.4"},{"groupId":"OG002","spread":"0.7","value":"2.1"},{"comment":"Due to insufficient number of participants in this age group (only 1 participant), standard deviation could not be calculated.","groupId":"OG003","spread":"NA","value":"3.8"}]}],"title":"Total (Children + Adolescents;n=4; n=10; n=6; n=1)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"description":"Concentration of dasatinib in CSF was assessed only in participants who had lumbar puncture during the treatment. y=years","dispersionType":"Standard Deviation","groups":[{"description":"Dasatinib 60 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG000","title":"Dasatinib 60 mg/m^2"},{"description":"Tablets, Oral; If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Dasatinib 80 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG001","title":"Dasatinib 80 mg/m^2"},{"description":"Tablets, Oral; If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Dasatinib 100 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG002","title":"Dasatinib 100 mg/m^2"},{"description":"Tablets, Oral; If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Dasatinib 120 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG003","title":"Dasatinib 120 mg/m^2"}],"paramType":"MEAN","populationDescription":"All treated participants with CSF samples available. n=number of PK parameters included. Each participant could have more than 1 CSF profiles sampled, depending on the number of times the dose of dasatinib was escalated.","reportingStatus":"POSTED","timeFrame":"4 hours after oral dose","title":"Concentration of Dasatinib in Cerebrospinal Fluid (CSF) by Dose Level and Age Group","type":"SECONDARY","unitOfMeasure":"ng/mL"}